GoldenGolden
Advanced Search
Boston Scientific

Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that is headquartered in Marlborough, Massachusetts and was founded in 1979 by John Abele and Pete Nicholas.

The company is interested in providing medical solutions for patients and to improve the health of patients around the world. The company holds medical specialties including electrophysiology, female pelvic medicine, gastroenterology, gynecology, interventional cardiology, interventional radiology and oncology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, structural heart, urology, and vascular surgery.

The company looks to provide educational systems and programs to support healthcare professionals in the delivery of patient care worldwide. They offer procedural simulations and learning programs with globally-recognized faculty. They provide curriculums for their medical specialties. They also dedicate training centers around the world through institute for advancing science.

Timeline

April 16, 2019
In announcing its decision on Tuesday, the F.D.A. said that Boston Scientific and Coloplast, a Danish company, had not demonstrated a reasonable assurance of safety and effectiveness for the devices.
February 12, 2019
Boston Scientific launches AdVance XP male stress urinary incontinence sling - MassDevice
December 27, 2018
Boston Scientific acquires Millipede for $325m with an additional $125 million based on a commercial milestone.
November 2018
Boston Scientific agreed to offer roughly $4.24 billion to acquire BTG.
August 2018
Boston Scientific amends an existing $1 billion credit agreement to help fund the BTG acquisition.
January 2018
Boston Scientific initially invests $90 million into Millipede, with an option to acquire the remaining shares in the company for $325 million and an additional $125 million milestone payment.
2015
Boston Scientific moves to acquire the remote cardiac monitoring developer Preventice Solutions.
May 22, 2009
Boston Scientific raises a $30,000,000 series C round from Accuitive Medical Ventures, Boston Scientific, Finistere Ventures and ONSET Ventures.
October 23, 2006
Boston Scientific raises a $19,000,000 series B round from Boston Scientific and ONSET Ventures.
June 17, 2004
Boston Scientific raises a $9,000,000 series A round from ONSET Ventures.
Page 1 of 2

Funding rounds

Acquisitions

People

Name
Role
LinkedIn

Andy Pluemer

Advisor

Benjamin Cornell

Investor

Henry Bliss

Advisor

John G Herndon

Advisor

Further reading

Title
Author
Link
Type
Date

Boston Scientific and Osiris Therapeutics Announce Stem Cell Alliance: Alliance to develop and commercialize cardiovascular therapies using adult Mesenchymal Stem Cells | Osiris Therapeutics, Inc.

Osiris Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Conor Hale
October 6, 2021
FierceBiotech
The Canadian company's specialty includes minimally invasive platforms that allow surgeons to accurately cross the thin, internal barrier separating the heart's upper right and left chambers.
Andrea Park
September 21, 2021
FierceBiotech
The deal will see Boston Scientific put down about $269 million up front to acquire Devoro, in which it has been a strategic investor since 2019. Down the line, it'll pay out up to another $67 million as its new subsidiary hits certain unspecified clinical and regulatory milestones.
Andrea Park
September 20, 2021
FierceBiotech
Boston Scientific's tumor-targeting glass microbeads continue to shatter expectations for cancer treatment. The newly released results of a long-term study showed adding TheraSpheres to a chemotherapy regimen can extend survival for patients with colorectal cancer that has spread to the liver.
FinSMEs
September 16, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Conor Hale
August 30, 2021
FierceBiotech
Both minimally invasive devices are designed to reduce the long-term risk of stroke in patients with atrial fibrillation.
Andrea Park
August 19, 2021
FierceBiotech
Though many other software developers have created their own heart-mapping technologies, according to CardioNXT, its system is the first to also provide 3D navigation.
Conor Hale
August 11, 2021
FierceBiotech
The FDA continues to make single-use endoscopes available, with clearances for 3NT Medical and Boston Scientific.
Andrea Park
August 9, 2021
FierceBiotech
Boston Scientific initiated the recall at the beginning of June, and this month, the FDA gave it a Class I rating, indicating a serious risk of injury or death associated with use of the affected devices.
Conor Hale
July 27, 2021
FierceBiotech
The company posted net sales of about $3.08 billion for the second quarter of 2021, or a 53.6% gain over the same three months of the year before, when the first major wave of COVID-19 swept through the U.S.
Andrea Park
July 21, 2021
FierceBiotech
The idea of implanting a device inside the heart to block blood flow may sound counterintuitive, but in the case of left atrial appendage closure devices like Boston Scientific's Watchman FLX, that intentional blockage could save lives.
BioSpace
July 1, 2021
BioSpace
DiNAQOR today announced that it has expanded the company's board of directors with three new cardiovascular industry and academic experts: Louis G. Lange , M.D., Ph.D.; Steven Zelenkofske , D.O., M.S.; and Silke Rickert-Sperling , M.D.
BioSpace
June 28, 2021
BioSpace
Presidio Medical, Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, today announced that Michael Onuscheck has been named the incoming Chief Executive Officer and Chairman of the Board.
Andrea Park
June 24, 2021
FierceBiotech
Boston Scientific exercised its option to acquire Farapulse, after already holding a 27% stake in the company, and plans to put down about $295 million to pick up the remainder.
Boston Scientific Corporation
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance,...
Conor Hale
May 16, 2021
FierceBiotech
Remember the FDA's limits on paclitaxel-laden devices? Think again: An audit of nearly four years of Medicare data spanning more than 168,000 beneficiaries found no evidence of additional harm with balloons and stents coated with the chemotherapy drug compared to bare ones.
Conor Hale
May 14, 2021
FierceBiotech
A quick detour during surgery to close off the left atrial appendage--a small pouch in the wall of the heart muscle, where blood can pool and form clots--could help reduce the overall risk of stroke in patients with atrial fibrillation, researchers said.
Technavio
April 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- The ureteroscopy devices market is expected to grow by USD 189.68 million during 2021-2025, according to Technavio. The report offers a...
BioSpace
April 27, 2021
BioSpace
On the heels of its April 7 launch announcement, Xenter, Inc. (XenterMD.com), the world's first start-up Device-Data-Drug healthcare technologies company, today announced that James R. Tobin has been appointed to the company's Board of Directors.
BioSpace
April 22, 2021
BioSpace
BIOMODEX®, a pioneering digital health company that offers advanced 3D printed solutions for patient-specific rehearsal and physician training, today announced the appointment of Rich Ferrari to its Board of Directors.
Conor Hale
March 29, 2021
FierceBiotech
Shortly after winning an FDA approval this month, Boston Scientific delivered new data showing its radioactive glass microsphere implants can safely shrink inoperable liver tumors and help patients live longer.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.